


FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5

FIGURE 6





FIGURE 7





A
(MOG)
(OVA)
1:10³
1:10⁴
1:10⁵
% of Max
Anti-Mouse IgG
B
C
MOG
MOG
OVA
MCF
OD (450 nm)
(MOG)
(OVA)
Sera Dilution (1:n)

FIGURE 8




FIGURE 9




FIGURE 10






FIGURE 11

(i)



(ii)



(iii)




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15






FIGURE 16

(i)



(ii)



(iii)




FIGURE 17




FIGURE 18




FIGURE 19



Number of particles
140
120
100
80
60
40
20
0
20
50
70
90
110
130
150
170
190
210
230
250
270
290
Size (nm)

FIGURE 20



PHA
PHA
PHA
PHA
PHA
Isolated antigen displaying PHA granules
antiserum containing anti-antigen antibodies
PHA
+
labelled
secondary antibody
PHA
antigen-specitic antibody
labelled secondary antibody
Antigen
Linker
particle binding domain

FIGURE 21